Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.

Stanford scientists devised a blood-based test that accurately identified people with chronic fatigue syndrome, a new study reports.

Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.

In preclinical trials, Stanford scientists and their collaborators harnessed the gene-editing system CRISPR-Cas9 to replace the mutated gene underpinning the devastating immune disease.

To treat diabetes directly, rather than manage its symptoms, doctors need a way to get drugs to cells that produce insulin. The key, Stanford researchers report, may be those cells’ affinity for zinc.

A study out of Stanford in which blood sugar levels were continuously monitored reveals that even people who think they’re “healthy” should pay attention to what they eat.

Mary Leonard, chair of the Department of Pediatrics at Stanford, works to understand exactly how chronic diseases hurt children’s bone health.

With the grant, Stanford joins 16 other federal research centers across the country dedicated to the prevention and treatment of diabetes.

In a randomized clinical trial conducted by researchers at Stanford and more than 100 other medical centers, psoriatic arthritis patients given an injectable biologic drug for 24 weeks showed substantial improvement compared with patients who received placebo injections.

Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it.